Advertisement
ETNB 외환 뉴스
89bio Reports Positive Topline Data From Extended Phase 2b ENLIVEN Trial Of Pegozafermin
Biopharmaceutical company 89bio, Inc. (ETNB) announced Monday positive topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis (NASH).
RTTNews
|
588 일 전
